(Q45960718)

18 December 2017

title

Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. (English)

1 reference

18 December 2017

author name string

Brian Shuch

1

1 reference

18 December 2017

Jeff C La Rochelle

2

1 reference

18 December 2017

Jon Wu

3

1 reference

18 December 2017

Tobias Klatte

4

1 reference

18 December 2017

Stephen B Riggs

5

1 reference

18 December 2017

Fairooz Kabbinavar

6

1 reference

18 December 2017

Arie S Belldegrun

7

1 reference

18 December 2017

Allan J Pantuck

8

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

18 December 2017

published in

Cancer

1 reference

18 December 2017

volume

113

1 reference

18 December 2017

issue

6

1 reference

18 December 2017

page(s)

1324-1331

1 reference

18 December 2017

The natural history of metastatic renal cell carcinoma: a computer analysis

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Validation of the ucla integrated staging system for patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Physiological basis of fatigue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

The role of transarterial embolization in the treatment of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23708

7 January 2021

Identifiers

DOI

10.1002/CNCR.23708

1 reference

18 December 2017

1 reference

18 December 2017